CRISPR and Cancer

In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies...

Extended survival times and inhibited growth of patient-derived glioblastoma brain tumours have been achieved in mice with CRISPR-Cas9 mediated...

Caribou Biosciences recently shared positive clinical data for its CRISPR-edited CAR-T cell therapy, CB-010, in patients with relapsed/refractory B...

Researchers from Italy’s Ospedale San Raffaele Scientific Institute, in collaboration with Intellia Therapeutics, have used CRISPR to introduce...

This week's clinical update includes news from Allogene Therapeutics and Graphite Bio. The U.S. Food and Drug Administration (FDA) recently granted...

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

Resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer. By profiling the spectrum of outcomes arising from...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...